Peter Puccetti Divests Interest in Goodwood Inc., Reducing Stake in COSCIENS Biopharma to 0.5%

Peter Puccetti and Puccetti Funds Management Inc. filed this Amendment No. 3 to Schedule 13D to report a significant reduction in beneficial ownership of COSCIENS Biopharma Inc. (CSCIF). Effective March 1, 2026, Puccetti's wholly-owned entity, 1354037 Ontario Inc., sold its entire equity interest in Goodwood Inc. to Nour Private Management Inc. As a result of this transaction, Puccetti no longer owns or controls Goodwood Inc. or the Goodwood Fund, which holds 241,570 shares. Consequently, the Joint Filing Agreement between the parties was terminated, and they are no longer acting as a group. The Reporting Persons' beneficial ownership decreased from approximately 8.2% (257,257 shares) to 0.5% (15,687 shares). Despite the divestment, Puccetti continues to serve as the interim CEO and Chairman of the Board for the Issuer. He also entered into transitional advisory arrangements with Nour, though these roles do not grant him voting or dispositive power over the shares held by the Goodwood Fund.